Sigyn Therapeutics Announces Board and Executive Changes
Ticker: SIGY · Form: 8-K · Filed: Jan 16, 2025 · CIK: 1642159
| Field | Detail |
|---|---|
| Company | Sigyn Therapeutics, Inc. (SIGY) |
| Form Type | 8-K |
| Filed Date | Jan 16, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $30,000, $50,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, compensation
TL;DR
Sigyn Therapeutics shakes up board & exec comp. New faces, new pay plans.
AI Summary
Sigyn Therapeutics, Inc. announced on January 11, 2025, changes in its board of directors and executive compensation. The filing details the departure of certain officers and directors, the election of new directors, and adjustments to compensatory arrangements for key personnel.
Why It Matters
Changes in a company's leadership and compensation structures can signal shifts in strategy or operational focus, potentially impacting future performance and investor confidence.
Risk Assessment
Risk Level: medium — Changes in board and executive leadership can introduce uncertainty about future strategy and operational stability.
Key Players & Entities
- Sigyn Therapeutics, Inc. (company) — Registrant
- January 11, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 000-55575 (filing_id) — Commission File Number
- 84-4210559 (tax_id) — IRS Employer Identification No.
- 2468 Historic Decatur Road, Suite 140, San Diego, California (address) — Business address
FAQ
What specific roles have been affected by the departure of officers or directors?
The filing indicates the departure of certain officers and directors, but does not specify the exact roles in this excerpt.
Who are the newly elected directors?
The filing mentions the election of new directors but does not name them in this excerpt.
What are the details of the compensatory arrangements for certain officers?
The filing states that compensatory arrangements of certain officers are being addressed, but the specific details are not provided in this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on January 11, 2025.
What is the state of incorporation for Sigyn Therapeutics, Inc.?
Sigyn Therapeutics, Inc. is incorporated in Delaware.
Filing Stats: 670 words · 3 min read · ~2 pages · Grade level 11.8 · Accepted 2025-01-16 17:09:53
Key Financial Figures
- $30,000 — irectors, namely, (i) an annual payment $30,000 paid in equal quarterly installments, a
- $50,000 — k units with a grant date fair value of $50,000, or at the discretion of the Directors,
Filing Documents
- form8-k.htm (8-K) — 37KB
- 0001493152-25-002575.txt ( ) — 202KB
- sigy-20250111.xsd (EX-101.SCH) — 3KB
- sigy-20250111_lab.xml (EX-101.LAB) — 33KB
- sigy-20250111_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SIGYN THERAPEUTICS, INC. Date: January 16, 2025 By: /s/ James A. Joyce James A. Joyce, Chairman and CEO